MWNA
AVDL

Marshall Wace North America’s Avadel Pharmaceuticals AVDL Stock Holding History

Marshall Wace North America’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,517
Closed -$111K – 1420
2017
Q4 		$111K Buy
+13,517
New +$127K ﹤0.01% 1308

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Marshall Wace North America's AVDL Position: Q1 2018 in Review

Marshall Wace North America sold out of Avadel Pharmaceuticals (AVDL) in Q1 2018, closing a stake of 13,517 shares — an estimated $111K sold.

Marshall Wace North America first reported a position in AVDL in Q4 2017 and held it in 1 quarter. The position peaked at $111K in Q4 2017. 80 funds tracked by Wall St. Rank hold AVDL as of Q1 2018.

  • Marshall Wace North America reported no remaining Avadel Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Marshall Wace North America sold 13,517 Avadel Pharmaceuticals shares in Q1 2018, an estimated $111K.
  • Marshall Wace North America first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Marshall Wace North America's Avadel Pharmaceuticals position peaked at $111K in Q4 2017.
  • 80 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2018.

Based on Marshall Wace North America's 13F filing for Q1 2018, filed 15 May 2018.